HBSP (USA)
-
Preparing for a Pandemic (Spanish version)
Staples, Jeffrey; Dowell, Scott F.; Bresee, Joseph S.; Nohria, Nitin; Bennis, Warren G.; Fischhoff, Baruch; MacGowan, William; Brilliant, Larry; Susser, Peter; Cooper, Sherry; Dobson, Wendy; Golden, Brian R.Article HBS-F0605AThis month, all of Harvard Business Review's Forethought contributions address avian influenza, its potential to become a pandemic, and the red flags this possibility raises for businesses. Jeffrey Staples warns that the H5N1 strain of the avian flu represents a new class of global threat and urges companies to plan accordingly. Scott F. Dowell and Joseph S. Bresee show how mutations of the virus could boost its ability to spread from person to p...Starting at €8.20
-
GlaxoSmithKline in China (A)
Quelch, John A.; Rodriguez, MargaretCase HBS-514049-EMarketingFour GlaxoSmithKline employees were accused of bribing Chinese health care workers to prescribe the company's drugs. The accusations brought to light the questionable incentive structures of the Chinese health care system and the pressure on companies to adhere to local customs while still observing local laws.Starting at €8.20
-
GlaxoSmithKline in China (B)
Quelch, John A.; Rodriguez, MargaretCase HBS-514050-EMarketingIn 2013, Chinese investigators detained four GSK employees for allegedly bribing health care staff to sell GSK pharmaceuticals. A month later, GSK's Asia Pacific regional president, Abbas Hussain, said the company would help identify corrupt practices. Two days later, GSK's CEO, Andrew Witty, called the allegations "shameful" and said the company would use the opportunity to "make changes."Starting at €5.74
-
GlaxoSmithKline in China (C)
Quelch, John A.; Rodriguez, MargaretCase HBS-514092-EMarketingThis case is a follow up to GlaxoSmithKline (A), 514049 and GlaxoSmithKline (B), 514050.Starting at €5.74